Bronchoscopy

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
Medical Devices, Surgery, FDA, Genetics, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Oncology, Research, Lung cancer, Growth, CFO, Laboratory developed test, Form, Patient, Accounting, Bronchoalveolar lavage, Sale, Acquisition, Cancer, CPA, CAP, Insurance, MBA, Lung, BAL, BIAF, Bronchoscopy, LDT, Optimism, Medicare, Calendar, Marketing, CMS, Physician, Pharmaceutical industry

Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.

Key Points: 
  • Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.
  • Research and development expenses were $432,000 for the fourth quarter of 2023, compared with $429,000 for the comparable period in 2022.
  • Selling, general and administrative expenses were $2.2 million for the fourth quarter of 2023, compared with $1.2 million for the comparable period in 2022.
  • Net loss for the fourth quarter of 2023 was $2.4 million, compared with a net loss of $1.7 million for the comparable period in 2022.

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, February 26, 2024
Research, Investment, Form 10-K, Sale, Form, HSV, Society, KRYS, Immunotherapy, Trial of the century, Genotype, Eye, PI, Krystal, Transgene, European Medicines Agency, Security (finance), Pharmacology, NCT, DEB, Jeune, ID, ODD, AATD, Safety, Survival, Medicaid, IND, Bronchoscopy, IL-12, Gene, MAA, FDA, Patent, Priority review, Cell, Lung, Patient, Medicine, Pharmaceutical industry

(the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Key Points: 
  • (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
  • Financial results for the quarter ended December 31, 2023:
    Cash, cash equivalents, and investments totaled $594.1 million on December 31, 2023.
  • The Company recorded net product revenue of $42.1 million from sales of VYJUVEK during the quarter ended December 31, 2023.
  • For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the Securities and Exchange Commission.

Hemet Global Medical Center Voted “Best Hospital” in the Inland Empire by Press-Enterprise Readers for 2023

Retrieved on: 
Tuesday, October 17, 2023
Hospital, Acquisition, Pastoral Care, CT scan, Hospital Insurance and Diagnostic Services Act, Bankruptcy, ERCP, Urology, Arthroscopy, U.S. News & World Report Best Hospitals Rankings, EKG, TEE, Interventional radiology, Health, The Press-Enterprise, Medical-surgical nursing, EEG, Prenatal development, Nursing, Emergency service, KPC, Minimally invasive spine surgery, Lactation consultant, Nuclear medicine, EGD, MRI, ICU, Professional, Social work, Patient, Pound (currency), Mammography, Echocardiography, Bronchoscopy, Cardiology, Ultrasound, Telemetry, Inland Empire, Colonoscopy

ORANGE, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemet Global Medical Center (“HGMC”), a KPC Health hospital, has been voted “Best Hospital” in the Inland Empire for 2023 by Press-Enterprise readers.

Key Points: 
  • ORANGE, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Hemet Global Medical Center (“HGMC”), a KPC Health hospital, has been voted “Best Hospital” in the Inland Empire for 2023 by Press-Enterprise readers.
  • The distinguished honor is part of the Press-Enterprise’s 28th Annual “Best of Inland Empire” Readers’ Choice awards for local businesses.
  • “Prior to KPC Health’s acquisition of Hemet Global Medical Center, this was a hospital on the brink of bankruptcy that many believed could not be saved,” said Dr. Kali P. Chaudhuri, Founder and Chairman of the KPC Group.
  • KPC Health’s current system of hospitals includes seven full-service acute care hospitals located throughout southern California, including Orange County Global Medical Center, Chapman Global Medical Center, Anaheim Global Medical Center, South Coast Global Medical Center, Hemet Global Medical Center, Menifee Global Medical Center, and Victor Valley Global Medical Center.

Bronchoscopy Market Soars to $3.9 Billion by 2028: Comprehensive Report Unveils Growth Potential - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 11, 2023
Health, Medical Supplies, Medical Devices, Patent, Diagnosis, COVID-19, Pediatrics, Bronchoscopic lung volume reduction, ESG, Prevalence, Wilford Hall Ambulatory Surgical Center, Patient, Bronchoscopy, Growth, Abdominal ultrasonography, Research, Renewable energy, Medical device, Video game, Pharmaceutical industry, Retail, Social

The global bronchoscopy market, valued at $2.5 billion in 2022, is projected to experience robust growth, reaching approximately $3.9 billion by the end of 2028, with a compound annual growth rate (CAGR) of 7.4%.

Key Points: 
  • The global bronchoscopy market, valued at $2.5 billion in 2022, is projected to experience robust growth, reaching approximately $3.9 billion by the end of 2028, with a compound annual growth rate (CAGR) of 7.4%.
  • This significant market expansion is detailed in a comprehensive report that delves into market dynamics, drivers, challenges, and growth opportunities.
  • An estimate of the actual market size and a revenue forecast for the global bronchoscopy market, with corresponding market share analysis.
  • The bronchoscopy market is witnessing significant growth due to the increasing prevalence of airway and lung diseases globally.

Karius Test® Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood Cancer

Retrieved on: 
Tuesday, October 10, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Science, Oncology, Diagnosis, Memorial Sloan Kettering Cancer Center, University of Pittsburgh Medical Center, Immunodeficiency, Fred Hutchinson Cancer Research Center, Death, Plasma, DNA, The Study, Risk, National Cancer Institute, Weill Cornell Medicine, University, Loris Karius, MD Anderson Cancer Center, University of Colorado Denver, Principal, University of California, Detection, City, University of Colorado, Bone marrow, Publication, Infection, Bronchoscopy, Duke University Health System, Metagenomics, Patient, Vaccine, Pharmaceutical industry, Pneumonia

“Often clinicians must weigh the risks of invasive procedures in medically fragile patients with an anticipated low diagnostic yield.

Key Points: 
  • “Often clinicians must weigh the risks of invasive procedures in medically fragile patients with an anticipated low diagnostic yield.
  • Identifying the specific cause of pneumonia in patients with blood cancers who are often severely immunocompromised is difficult and critically important to successful treatment.
  • “This well-designed clinical trial conducted at leading academic centers shows that the Karius Test is highly valuable in immunocompromised patients with suspected infection,” said Dr. Ned Sharpless, former Director, National Cancer Institute, and newest Karius board member.
  • “These patients have much to gain through an improved etiologic diagnosis, and the better and more directed treatment of these infections that make this possible,” said Brad Perkins, Chief Medical Officer at Karius.

18.0% CAGR Growth Expected in the Global Single Use-Disposable Endoscopes Market: Meeting Clinical Needs with Innovative Solutions - ResearchAndMarkets.com

Retrieved on: 
Friday, September 8, 2023
Medical Supplies, Health, Fungal infection, Dentistry, ENT, COPD, Stenosis, Single, Bleeding, Urinary tract infection, Prevalence, HAI, Hospital, Bronchoscopy, Bronchoscopic lung volume reduction, Cancer, Inflammation, Compound annual growth rate, GERD, Incidence, Anemia, Conditional sentence, Growth, Ulcer, FDA, Medical device, Endoscopy

Its minimally invasive nature enhances patient comfort, facilitating early detection and interventions that can potentially lead to improved outcomes.

Key Points: 
  • Its minimally invasive nature enhances patient comfort, facilitating early detection and interventions that can potentially lead to improved outcomes.
  • The Single Use-Disposable Endoscopes Market is predicted to witness a Compound Annual Growth Rate (CAGR) of 18.04% from 2022 to 2030.
  • Regulatory approvals, like the recent FDA endorsement for innovative disposable endoscopes designed for sterile procedures, are driving sales.
  • Increased awareness and cost-effective options drive the demand for single use disposable endoscopes in the region.

The Inner Circle Acknowledges, Dr. Diana Kolman as a Pinnacle Platinum Healthcare Professional for her work as an Interventional Pulmonologist

Retrieved on: 
Thursday, July 6, 2023
Interventional pulmonology, Critical care, BS, Surgeon, Body cavity, Physician, Education, Internal medicine, COVID-19, Cancer, Respiratory system, Multimedia, American Thoracic Society, Senior, Lung, Inner circle, Rutgers University, Drexel, Cooper University Hospital, System, MD, Patient, Ross University School of Medicine, Child, American Board of Internal Medicine, Fellow, Physics, Capital Health, Temple University School of Medicine, Nursing care plan, Oncology, Smoking, Family, Mediastinum, Interior design, Nursing, Biology, Bronchoscopy

MOUNT LAUREL, N.J., July 6, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Diana Kolman is acknowledged as a Pinnacle Platinum Healthcare Professional for her work as an Interventional Pulmonologist.

Key Points: 
  • MOUNT LAUREL, N.J., July 6, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Diana Kolman is acknowledged as a Pinnacle Platinum Healthcare Professional for her work as an Interventional Pulmonologist.
  • Dr. Kolman began her pursuit of higher education at Rutgers University where she received a BS in Biology and Physics.
  • She is known for being clear and honest with her patients regarding their diagnoses and works to give them several options for treatment.
  • According to Dr. Kolman, the physicians at Capital Health – Pulmonology Specialists diagnose and treat conditions that affect the lungs and respiratory system.

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

Retrieved on: 
Wednesday, November 30, 2022
Biotechnology, General Health, Health, Medical Devices, PMDA, Medicines and Healthcare products Regulatory Agency, American Journal of Respiratory and Critical Care Medicine, Lung transplantation, Physician, GOLD, Statistics Bureau (Japan), Degenerative disease, Security (finance), Corporation, Diaphragm, Endobronchial valve, Patient, Respiratory Medicine, FDA, Kawasaki, Global Initiative, Lung, Drug Quality and Security Act, Zephyr, Walking, Atmosphere, Bronchoscopy, Safety, IMPACT, MHLW, Medication, Pharmaceuticals and Medical Devices Agency, INT, Quality of life, American Journal, Critical Care Medicine (journal), Medical imaging, Silviculture, Health, COPD

Pulmonx intends to collaborate with the Japanese MHLW to gain reimbursement prior to commercialization in Japan to ensure broader access to its innovative and clinically proven treatment.

Key Points: 
  • Pulmonx intends to collaborate with the Japanese MHLW to gain reimbursement prior to commercialization in Japan to ensure broader access to its innovative and clinically proven treatment.
  • The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema.
  • Physicians use the Pulmonx Chartis Pulmonary Assessment System to help identify potential responders to Zephyr Valve treatment.
  • Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following its designation as a breakthrough device.

Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

Retrieved on: 
Wednesday, November 16, 2022
Hypertension, Bradycardia, Ventilation, Itch, Hypoxia, Hypoventilation, Colonoscopy, Rash, GABA, Flumazenil, History, Placenta, Liver, III, Breast milk, Analgesic, ASA, Obstructive sleep apnea, Brain, Life, Safety, Patient, Apnea, Anaphylaxis, NMDA, Vital signs, Airway obstruction, Anesthesia, Maintenance, Benzodiazepine, Propofol, Hives, CNS, Patent, Government budget balance, CIV, Confusion, Systolic hypertension, Lethargy, Death, Hypotension, Hypotonia, IV, Human, Pregnancy, Bronchoscopy, Coma, Dentistry, Liquor, Pharmaceutical industry

WOODCLIFF LAKE, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the following speakers and world-renowned Key Opinion Leaders will be featured at the Company’s Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET:

Key Points: 
  • Resuscitative drugs, and age- and size-appropriate equipment for bag-valve-maskassisted ventilation must be immediately available during administration of BYFAVO.
  • Concomitant use of benzodiazepines, including BYFAVO, and opioid analgesics may result in profound sedation, respiratory depression, coma, and death.
  • The sedative effect of intravenous BYFAVO can be accentuated by concomitantly administered CNS depressant medications, including other benzodiazepines and propofol.
  • BYFAVO is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40.

Global Bronchoscopes Market Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022
Medical Devices, Health, SWOT analysis, Investment, Sarcoidosis, Pneumonia, Respiratory tract, Strategic planning, SWOT, Market access, Degenerative disease, Tuberculosis, LIBOR market model, Neoplasm, Cryotherapy, High-dependency unit, CMO, Reading, Intensive care unit, Bronchoscopy, Internet, Model, ASP, COVID-19, Airway management, Country, Region, Epidemiology, Retail, Pharmaceutical industry, Healthcare, Marketing, Risk management, Management, Video game, Bronchoscopic lung volume reduction (BLVR), Forecast

These could be of following types: Rigid Bronchoscopes, Flexible Fibre Bronchoscopes, Flexible Video Bronchoscopes, and Mobile Bronchoscopes.

Key Points: 
  • These could be of following types: Rigid Bronchoscopes, Flexible Fibre Bronchoscopes, Flexible Video Bronchoscopes, and Mobile Bronchoscopes.
  • Global, Regional and Country level market specific insights:
    Qualitative market specific information is available with global trends further broken down into regional trends.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Bronchoscopes market in the future.
  • Track device sales in the global and country-specific Bronchoscopes market from 2015-2030.